Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 16, 2019 / 04:20PM GMT
Release Date Price: $15.92 (+0.82%)
Ashwani Verma
BofA Merrill Lynch, Research Division - Research Analyst

So our next company here is Halozyme Therapeutics, and with me is Laurie Stelzer. My name is Ashwani Verma. I work with the U.S. major and specialty pharma team at Bank of America. And Laurie, the stage is yours. Let's look at the slides.

Laurie D. Stelzer
Halozyme Therapeutics, Inc. - Senior VP & CFO

Terrific. Thank you, Ash. So good morning, everyone. I'm here today to talk about Halozyme and how we're building a premier biotechnology company, and we're doing this through 2 engines of growth. It's a very unique strategy, very different than many biotech companies, and I'll walk you through that strategy over the next 15 minutes. Naturally, I'll be making some forward-looking statements. So I'll point you to our website for a full list of our risks and uncertainties.

So as I mentioned, we have 2 engines for growth, we have our ENHANZE technology platform, and we have PEGPH20 oncology program. So on our ENHANZE technology platform, this is where -- it's based on a technology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot